Skip to content

Study · Randomized controlled trial · n = 20 · 2026

11 results

Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.

Gutierrez de Piñeres V, Ramirez-Cisneros A, Tamayo-Torres CS, Angelidi AM, Kavelidou M, Stefanakis K, Mantzoros CS

Diabetes research and clinical practice20 Jan 2026

PMID41571048 (opens in a new tab)DOI10.1016/j.diabres.2026.113113 (opens in a new tab)PepBankPUB-41571048
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide reduced body weight versus placebo.

    In plain wordsIn adults with obesity, liraglutide reduced body weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, and extremities).
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide reduced body mass index versus placebo.

    In plain wordsIn adults with obesity, liraglutide reduced body mass index more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, and extremities).
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide reduced total mass versus placebo.

    In plain wordsIn adults with obesity, liraglutide reduced total mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, and extremities).
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide reduced trunk mass versus placebo.

    In plain wordsIn adults with obesity, liraglutide reduced trunk mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTrunk mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, and extremities).
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide reduced hip mass versus placebo.

    In plain wordsIn adults with obesity, liraglutide reduced hip mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHip mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, and extremities).
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide reduced extremity mass versus placebo.

    In plain wordsIn adults with obesity, liraglutide reduced extremity mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseExtremity mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, and extremities).
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, absolute fat-free mass was slightly but significantly lower with liraglutide than placebo.

    In plain wordsIn adults with obesity, liraglutide produced a small but significant reduction in absolute fat-free mass versus placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAbsolute fat-free mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Absolute fat-free mass was slightly but significantly lower.
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide decreased absolute trunk lean mass versus placebo.

    In plain wordsIn adults with obesity, liraglutide decreased trunk lean mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAbsolute trunk lean mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Absolute lean mass in the trunk and extremities decreased, whereas relative lean mass and fat-free mass percentages remained stable at treatment completion.
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide decreased absolute extremity lean mass versus placebo.

    In plain wordsIn adults with obesity, liraglutide decreased extremity lean mass more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAbsolute extremity lean mass
    Study

    n = 20

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Absolute lean mass in the trunk and extremities decreased, whereas relative lean mass and fat-free mass percentages remained stable at treatment completion.
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, relative lean mass remained stable at treatment completion with liraglutide.

    In plain wordsIn adults with obesity, relative lean mass was reported stable at treatment completion with liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableRelative lean mass
    Study

    n = 20

    Analysis
    Secondary
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Absolute lean mass in the trunk and extremities decreased, whereas relative lean mass and fat-free mass percentages remained stable at treatment completion.
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, fat-free mass percentage remained stable at treatment completion with liraglutide.

    In plain wordsIn adults with obesity, fat-free-mass percentage was reported stable at treatment completion with liraglutide.

    Peptide
    Liraglutide
    Outcome
    Not applicableFat-free mass percentage
    Study

    n = 20

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg/day · 35 daysAs given in this study (human).

    Source sentences

    Summary
    Absolute lean mass in the trunk and extremities decreased, whereas relative lean mass and fat-free mass percentages remained stable at treatment completion.
    1 context sentence
    Summary · context
    Twenty adults with obesity received liraglutide 3.0 mg/day or placebo for 35 days in this crossover randomized controlled trial. In this secondary analysis, body composition was assessed by dual-energy X-ray absorptiometry at the end of each phase, while hormones were measured by ELISA at baseline a…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.